‘Screen all approach’ for HBV prior to chemotherapy most cost-effective

Screening all patients with solid tumors for hepatitis B before they underwent chemotherapy was the most cost-effective strategy, compared with not screening or only screening high-risk patients, according to a published study.The rates of prior HBV exposure among patients with newly diagnosed cancer ranged from 5.6% to 7.4% and many individuals are unaware of their infection, putting them at a high-risk for HBV reactivation during immunosuppressive therapy or cancer chemotherapy, according to Gauree G. Konijeti, MD, from the Scripps Clinic in California, and colleagues.“DeterminationRead More

Share on facebook
Share on twitter
Share on linkedin